• BMN 673: Splicing, HRD, and PARP Sensitivity

  2026-10-05

  BMN 673 (Talazoparib) offers a powerful lens for studying PARP-DNA complex trapping and DNA repair deficiency. This article connects its established pharmacology with new evidence linking spliceosome regulation, BRCA-related exon selection, and PARP inhibitor sensitivity in hepatocellular carcinoma.

• EZ Cap EGFP mRNA: Product Overview

  2026-10-05

  EZ Cap™ EGFP mRNA is a Cap 1 EGFP reporter mRNA product listed by APExBIO for research focused on delivery and transient expression. No matched paper evidence was supplied for this specific product listing.

• LMO2–LDB1 Signaling in Acute Myeloid Leukemia

  2026-10-04

  Lu and colleagues identify an LMO2/LDB1 protein complex as a functional regulator of AML cell survival and proliferation, extending mechanisms previously associated with hematopoietic development and T-cell leukemia into AML models. Their integrated perturbation, interaction-proteomics, transcriptomic, and chromatin-association evidence supports LDB1 as an AML dependency, while also showing that LMO2 can partially compensate for LDB1 loss.

• 3-Deazaadenosine Hydrochloride: Research Context

  2026-10-03

  A source-grounded overview of 3-Deazaadenosine hydrochloride as a reported S-adenosylhomocysteine hydrolase inhibitor, with emphasis on methylation biology, hepatic stellate cell research, evidence strength, and limitations. The supplied liver-fibrosis study supports an IGF2BP1–TUBB4B–FAK mechanism but did not test 3-Deazaadenosine hydrochloride.

• Naloxone hydrochloride: Research Workflows

  2026-10-02

  Build cleaner receptor, neural stem cell, immune, and behavioral assays with Naloxone hydrochloride, a versatile opioid receptor antagonist. This guide combines solution-handling discipline with orthogonal controls that help separate receptor blockade from concentration-dependent and receptor-independent effects.

• AMG 9810 TRPV1 Antagonist Assay Workflows

  2026-10-01

  Build more interpretable TRPV1 experiments with AMG 9810, from capsaicin-evoked calcium imaging to CGRP secretion and sensory neuron signaling studies. The workflow adds solvent, pH, metabolic-stress, and viability controls so antagonist effects are not mistaken for general cellular dysfunction.

• SW033291 15-PGDH Inhibitor Workflows

  2026-10-01

  SW033291 connects nanomolar 15-PGDH target engagement with prostaglandin E2 elevation, hematopoietic stem cell expansion, and regeneration-focused assays. This practical workflow separates enzyme potency from cellular phenotype and shows how to evaluate emerging muscle-repair applications without overstating translational evidence.

• Acetylspiramycin (Spiramycin B): Research Guide

  2026-09-30

  Acetylspiramycin, also called Spiramycin B, is a 16-membered macrolide and bacterial protein synthesis inhibitor used in ribosomal, antimicrobial resistance, and host-response research. Product specifications support controlled in vitro studies, while a refractory ocular toxoplasmosis case illustrates why clinical observations must not be interpreted as proof of broad efficacy.

• Sodium Ascorbate: ROS Research Guide

  2026-09-30

  Sodium Ascorbate is a mineral salt of ascorbic acid used in preclinical redox and cancer-cell studies. Product documentation reports intracellular ROS induction, reduced tumor-cell proliferation and motility, and activity in glioblastoma models, but these findings do not establish clinical efficacy.

• Mouse Lung Organoid Kit for LNP Research

  2026-09-29

  Explore how the Mouse Lung Organoid Kit can support physiologically relevant evaluation of lung-targeted lipid nanoparticles, using recent LuT lipid findings to guide assay design, controls, and translational interpretation.

• CCK-8, Endogenous Opioids, and Morphine Withdrawal Anxiety

  2026-09-29

  Wen et al. showed that central cholecystokinin octapeptide (CCK-8) reduces anxiety-like behavior during morphine withdrawal in rats through a CCK1 receptor-dependent interaction with endogenous opioid signaling. The study connects negative affect during abstinence to a pharmacologically testable neuropeptide mechanism and identifies central CCK1 signaling as a potential target for opioid addiction and withdrawal studies.

• Dovitinib (TKI-258) for RTK Cancer Assays

  2026-09-28

  Dovitinib (TKI-258) turns broad RTK inhibition into a practical workflow for linking receptor dependence with ERK, STAT, viability, and apoptosis readouts. This guide combines concentration planning, orthogonal validation, and cheminformatics-informed controls to improve interpretation in multiple myeloma and hepatocellular carcinoma models.

• Mouse Lung Organoid Kit for LNP Research

  2026-09-28

  Use a mouse lung organoid workflow to compare candidate lung-directed lipid nanoparticles ex vivo, with controls that separate delivery, expression, editing, and toxicity. The featured study reports strong lung delivery in mice—but those in vivo results are a rationale for organoid testing, not a guarantee of organoid performance.

• SW033291: A Potent 15-PGDH Inhibitor

  2026-09-27

  SW033291 is a potent 15-PGDH inhibitor used to investigate prostaglandin E2 elevation and downstream regenerative biology. Product information reports nanomolar enzyme and cellular activity, while a 2026 mouse study supports 15-PGDH inhibition as a separate research direction for muscle repair during semaglutide-associated weight loss.

• AZ 10417808 for ATRX-Deficient Glioma Studies

  2026-09-26

  Use AZ 10417808 in a controlled, genotype-aware workflow to test whether a compound changes glioma-cell viability, alone or alongside temozolomide. The reference study supports ATRX status as a useful experimental variable, but the supplied product information does not specify AZ 10417808’s target or potency—so the first step is validating compound identity and assay conditions, not assuming a mechanism.

533 records 1/36 page Next 12345 下5页 Last page